Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: Analysis of 110 patients in real-life practice

Moises Labrador-Horrillo, Antonio Valero, Manuel Velasco, Ignacio Jáuregui, Joaquin Sastre, Joan Bartra, Juan Francisco Silvestre, Javier Ortiz De Frutos, Ana Gimenez-Arnau, Marta Ferrer

Research output: Contribution to journalArticleResearchpeer-review

63 Citations (Scopus)

Abstract

Objective: To collect data on the efficacy and safety of omalizumab in 110 patients from 9 Spanish hospitals suffering from chronic spontaneous urticaria (CSU) refractory to conventional treatment. Methods: A retrospective, descriptive analysis was performed, showing the data of 110 patients suffering from refractory CSU who received omalizumab as an off-label treatment in 9 Spanish hospitals from October 2009 to September 2012. Results: Ninety (81.8%) patients exhibited a complete or significant response, 12 (10.9%) had partial response, and 8 (7.2%) showed no response. Sixty-six (60%) patients were able to stop all concomitant medications, remaining asymptomatic treated with omalizumab alone. No serious adverse events were reported. Conclusions: Omalizumab shows excellent efficacy and safety profile in a large series of CSU patients in real-life practice. This drug will contribute to settle the debt with CSU patients contributing to restore their quality of life. © Informa UK, Ltd.
Original languageEnglish
Pages (from-to)1225-1228
JournalExpert Opinion on Biological Therapy
Volume13
Issue number9
DOIs
Publication statusPublished - 1 Sep 2013

Keywords

  • Chronic spontaneous urticaria
  • Chronic urticaria
  • CSU
  • Omalizumab

Fingerprint

Dive into the research topics of 'Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: Analysis of 110 patients in real-life practice'. Together they form a unique fingerprint.

Cite this